



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> <b>C07K 7/06, A61K 37/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/22338</b> <b>(43) International Publication Date:</b> 11 November 1993 (11.11.93)
<b>(21) International Application Number:</b> PCT/NL93/00093 <b>(22) International Filing Date:</b> 4 May 1993 (04.05.93) <b>(30) Priority data:</b> 92201252.1 5 May 1992 (05.05.92) EP (34) Countries for which the regional or international application was filed: NL et al. 92203870.8 10 December 1992 (10.12.92) EP (34) Countries for which the regional or international application was filed: NL et al. 93200243.9 1 February 1993 (01.02.93) EP (34) Countries for which the regional or international application was filed: NL et al. 93200621.6 5 March 1993 (05.03.93) EP (34) Countries for which the regional or international application was filed: NL et al. <b>(71) Applicant (for all designated States except US):</b> RIJKSUNIVERSITEIT LEIDEN [NL/NL]; Stationsweg 26, NL-2312 AV Leiden (NL).	<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> KAST, Wybe, Martin [NL/NL]; Maria Rutgersweg 106, NL-2331 NX Leiden (NL). MELIEF, Cornelis, Joseph, Maria [NL/NL]; Johan Vermeerstraat 15, NL-2102 BT Heemstede (NL). SETTE, Alessandro, D. [IT/US]; 5551 Linda Rosa Avenue, La Jolla, CA 92307 (US). SIDNEY, John, C. [US/US]; 8541 D Villa La Jolla Drive, La Jolla, CA 92037 (US). <b>(74) Agent:</b> SMULDERS, TH., A., H., J.; Vereenigde Octrooibureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL). <b>(81) Designated States:</b> AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE); OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS  <b>(57) Abstract</b>  A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Peptides of Human Papilloma Virus for use in human T cell response inducing compositions

Field of the invention

The invention is concerned with novel peptides derived from Human Papilloma Virus proteins and their use in pharmaceutical compositions for a prophylactic or therapeutic treatment of human individuals against Human Papilloma Virus-related diseases such as cervical cancer.

Background of the invention

Human Papilloma Viruses (HPVs) are implicated in the etiology of cervical cancer, the fifth most common cancer worldwide and the second cause of cancer-related death in women. If also other HPV-related cancers are taken into account, up to 10% of the worldwide mortality due to cancer is linked to HPVs. HPVs are double stranded circular DNA viruses of about 8 kilobases. Until now more than 60 genotypes have been described of which several are associated with cancer.

HPV-DNA can be found in cervical dysplastic lesions and in cervical carcinomas in which the percentage of HPV positivity increases up to 99% when the lesions progress towards malignancy. The most important HPV types associated with cervical carcinoma are HPV16 and 18 of which HPV16 alone accounts for more than 50% of the HPV positive cervical carcinomas.

The DNAs of several HPVs have been sequenced. The DNA open reading frames can be divided into early regions (E) and late regions (L). The E regions are coding for proteins needed for virus replication and transformation. The L regions encode viral capsid proteins. The E6 and E7 proteins are involved in the pathogenesis of HPV-induced abnormal cell proliferation and these

genes are expressed in tissue or tumor cells obtained from cervical cancers associated with HPV infection.

In addition, the E6 and E7 genes of HPV16 and HPV18 are capable of inducing epithelial cell transformation in the cell culture without the presence of other HPV genes indicating that at least part of the stimulation of cell proliferation caused by HPV infection is due to the E6 and E7 viral proteins.

Cytotoxic T lymphocytes (CTL) are of crucial importance in the resistance against virus infections and the immune surveillance against virus-induced tumors (reviewed by Kast and Melief, 1991). CTL specific for viruses or virus-induced tumors recognize short viral protein-derived peptides, of about 9 amino acids in length, that are bound to the antigen presenting groove of major histocompatibility complex (MHC) class I molecules (reviewed by Kast and Melief, 1991). Recently, in several virus systems vaccination with peptides recognized by antigen-specific CTL was shown to prevent lethal virus infections and to delay tumor growth in mice (reviewed by Kast and Melief, 1991, and by Reinholdsson-Ljunggren et al., 1992).

We have succeeded in the identification of viral peptides that bind to the groove of MHC class I molecules by using the antigen processing defective cell line 174CEM.T2 generated and provided by P. Cresswell (see Salter and Cresswell, 1986). This cell line expresses the human MHC class I HLA-A2.1 and HLA-B5 alleles of which only the HLA-A2.1 molecules are expressed as partly empty and unstable molecules that can be stabilized on the cell surface with exogenously added peptides. If incubation with peptide results in an increase in the cell surface expression of this MHC molecule, this implies that the peptide binds to the groove of the HLA-A2.1 molecule and is therefore a possible candidate to be recognized by CTL. The HLA-A2.1 molecule is the most frequent HLA molecule present in the Western European Caucasoid population. About 50% of this population expresses this allele.

Using the amino acid sequence of the E6 and E7 proteins of HPV16 and HPV18 (Seedorf et al., 1985) we generated all possible

nonapeptides (i.e. 9 amino acid long peptides) overspanning the entire E6 and E7 region. Every amino acid was used as a start amino acid for these 9-mer peptides. Every peptide was subjected individually to the above test to determine its capacity to bind to the HLA-A2.1 molecule. With respect to HPV16, we identified in total 10 peptides in the HPV16 E6 region and 8 in the HPV16 E7 region which bound to the HLA-A2.1 molecule in the above test. With respect to HPV18, in total 9 peptides in the HPV18 E6 region and 5 in the HPV18 E7 region were identified in the above test to bind to the HLA-A2.1 molecule. This implies that important candidate peptides of HPV16 and HPV18 for use as a vaccine in HLA-A2.1 positive humans have been identified.

By using a second approach, we succeeded to expand the list of HLA-A2.1 binding HPV peptides a little further and to determine HPV16 E6 and E7 peptides binding to other HLA molecules, viz. to the HLA-A1, HLA-A3.2, HLA-A11.2 and HLA-A24 molecules. Said second approach consisted of a competitive immunochemical peptide-MHC binding assay using purified class I molecules and radiolabeled consensus peptides.

20

#### Summary of the invention

An object of the present invention is to provide synthetic peptides which can be used for prevention, prophylaxis, therapy and treatment of cervical carcinoma and/or adenoma and other HPV-related, in particular HPV16- and/or HPV18-related diseases.

Another object of the invention is to provide a method of prophylactic or therapeutic treatment of cervical carcinoma and/or adenoma and other HPV-related, in particular HPV16- and/or HPV18-related diseases.

A further object of the present invention is to provide pharmaceutical compositions which can be used for prevention, prophylaxis, therapy and treatment of cervical carcinoma and/or adenoma and other HPV-related, in particular HPV16- and/or HPV18-related diseases.

This invention provides a peptide comprising an amino acid sequence derived from a protein of human papilloma virus (HPV), wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex (MHC) Class I molecule.

5 The present invention also provides specific peptides derived from the amino acid sequence of the E6 and E7 regions of HPV16 and HPV18 which, because of their capability to bind to HLA molecules, such as e.g. the HLA-A2.1, HLA-A1, HLA-A3.2, HLA-A11.2 or HLA-A24 protein, are candidate peptides to be included in human vaccines  
10 that can induce protective or therapeutic T cell responses against HPV16 and/or HPV18.

The novel peptides of the present invention are useful in pharmaceutical compositions, as screening tools and in the prevention, prophylaxis, therapy and treatment of HPV16- and/or  
15 HPV18-induced diseases or other conditions which would benefit from inhibition of HPV16 and/or HPV18 infection.

In a preferred embodiment of the invention, said amino acid sequence is derived from protein E6 or E7 of HPV16. In another preferred embodiment of the invention, said amino acid sequence is  
20 derived from protein E6 or E7 of HPV18.

Preferably, said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.

More specifically, this invention provides a peptide comprising an amino acid sequence derived from protein E6 or E7 of  
25 HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

	AMFQDPQER	(residues 7- 15 of HPV16 protein E6)
	KLPQLCTEL	(residues 18- 26 of HPV16 protein E6)
30	QLCTELQTT	(residues 21- 29 of HPV16 protein E6)
	LCTELQTTI	(residues 22- 30 of HPV16 protein E6)
	ELQTTIHDI	(residues 25- 33 of HPV16 protein E6)
	LQTTIHDI	(residues 26- 34 of HPV16 protein E6)
	TIHDIILEC	(residues 29- 37 of HPV16 protein E6)
35	IHDIILECV	(residues 30- 38 of HPV16 protein E6)
	CVYCKQQLL	(residues 37- 45 of HPV16 protein E6)

FAFRDLCIV (residues 52- 60 of HPV16 protein E6)  
 KISEYRHYC (residues 79- 87 of HPV16 protein E6)  
 PLCDLLIRC (residues 102-110 of HPV16 protein E6)  
 TLHEYMLDL (residues 7- 15 of HPV16 protein E7)  
 5 YMLDLQPET (residues 11- 19 of HPV16 protein E7)  
 MLDLQPETT (residues 12- 20 of HPV16 protein E7)  
 RLCVQSTHV (residues 66- 74 of HPV16 protein E7)  
 TLEDLLMGT (residues 78- 86 of HPV16 protein E7)  
 LLMGTLGIV (residues 82- 90 of HPV16 protein E7)  
 10 GTLGIVCPI (residues 85- 93 of HPV16 protein E7)  
 TLGIVCPIC (residues 86- 94 of HPV16 protein E7), and

a fragment, homolog, isoform, derivative, genetic variant  
 or conservative variant of any one of these amino acid sequences  
 which has the ability to bind to human MHC Class I allele HLA-

15 A2.1.

More specifically, this invention provides a peptide  
 comprising an amino acid sequence derived from protein E6 or E7 of  
 HPV18, wherein said amino acid sequence has the ability to bind to  
 human MHC Class I allele HLA-A2.1 and is selected from the group

20 consisting of:

KLPDLCTEL (residues 13- 21 of HPV18 protein E6)  
 SLQDIEITC (residues 24- 32 of HPV18 protein E6)  
 LQDIEITCV (residues 25- 33 of HPV18 protein E6)  
 EITCVYCKT (residues 29- 37 of HPV18 protein E6)  
 25 KTVLELTEV (residues 36- 44 of HPV18 protein E6)  
 ELTEVFEEFA (residues 40- 48 of HPV18 protein E6)  
 FAFKDLFVV (residues 47- 55 of HPV18 protein E6)  
 DTLEKLTNT (residues 88- 96 of HPV18 protein E6)  
 LTNTGLYNL (residues 93-101 of HPV18 protein E6)  
 30 TLQDIVLHL (residues 7- 15 of HPV18 protein E7)  
 FQQLFLNTL (residues 86- 94 of HPV18 protein E7)  
 QLFLNTLSF (residues 88- 96 of HPV18 protein E7)  
 LFLNTLSFV (residues 89- 97 of HPV18 protein E7)  
 LSFVCPWCA (residues 94-102 of HPV18 protein E7), and

35 a fragment, homolog, isoform, derivative, genetic variant  
 or conservative variant of any one of these amino acid sequences

which has the ability to bind to human MHC Class I allele HLA-A2.1.

According to another preferred embodiment of this invention, said amino acid sequence has the ability to bind to human MHC

5 Class I allele HLA-A1.

More specifically, this invention provides a peptide comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A1 and is selected from the group

10 consisting of:

YRDGNPYAV	(residues 61- 69 of HPV16 protein E6)
WTGRCMSCC	(residues 139-147 of HPV16 protein E6)
MSCCRSSRT	(residues 144-152 of HPV16 protein E6)
TTDLICYEQ	(residues 19- 27 of HPV16 protein E7)
15 EIDGPAGQA	(residues 37- 45 of HPV16 protein E7)
HVDIRTLED	(residues 73- 81 of HPV16 protein E7), and

a fragment, homolog, isoform, derivative, genetic variant or conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A1.

20 According to another preferred embodiment of this invention, said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A3.2.

More specifically, this invention provides a peptide comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A3.2 and is selected from the group consisting of:

AMFQDPQER	(residues 7- 15 of HPV16 protein E6)
IILECVYCK	(residues 33- 41 of HPV16 protein E6)
30 CVYCKQQLL	(residues 37- 45 of HPV16 protein E6)
VYCKQQLLR	(residues 38- 46 of HPV16 protein E6)
QQLLRREVV	(residues 42- 50 of HPV16 protein E6)
IVYRDGNPY	(residues 59- 67 of HPV16 protein E6)
YAVCDKCLK	(residues 67- 75 of HPV16 protein E6)
35 AVCDKCLKF	(residues 68- 76 of HPV16 protein E6)
VCDKCLKFY	(residues 69- 77 of HPV16 protein E6)

	KFYISKISEY	(residues 75- 83 of HPV16 protein E6)
	KISEYRHYC	(residues 79- 87 of HPV16 protein E6)
	ISEYRHYCY	(residues 80- 88 of HPV16 protein E6)
	RHYCYSLYG	(residues 84- 92 of HPV16 protein E6)
5	SLYGTITLEQ	(residues 89- 97 of HPV16 protein E6)
	TTLEQQYNK	(residues 93-101 of HPV16 protein E6)
	QQYNKPLCD	(residues 97-105 of HPV16 protein E6)
	LIRCINCQK	(residues 107-115 of HPV16 protein E6)
	HLDDKKQRFH	(residues 125-133 of HPV16 protein E6)
10	CMSCCRSSR	(residues 143-151 of HPV16 protein E6)
	SCCRSSRTR	(residues 145-153 of HPV16 protein E6)
	CCRSSRTRR	(residues 146-154 of HPV16 protein E6)
	HYNIVTFCC	(residues 51- 59 of HPV16 protein E7)
	YNIVTFCKK	(residues 52- 60 of HPV16 protein E7)
15	CCKCDSTLR	(residues 58- 66 of HPV16 protein E7)
	KCDSTLRLC	(residues 60- 68 of HPV16 protein E7), and

a fragment, homolog, isoform, derivative, genetic variant or conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-

20 A3.2.

According to another preferred embodiment of this invention, said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A11.2.

25 More specifically, this invention provides a peptide comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A11.2 and is selected from the group consisting of:

	AMFQDPQER	(residues 7- 15 of HPV16 protein E6)
30	IILECVYCK	(residues 33- 41 of HPV16 protein E6)
	CVYCKQQLL	(residues 37- 45 of HPV16 protein E6)
	VYCKQQLLR	(residues 38- 46 of HPV16 protein E6)
	QQLLRREVY	(residues 42- 50 of HPV16 protein E6)
	IVYRDGNPY	(residues 59- 67 of HPV16 protein E6)
35	YAVCDKCLK	(residues 67- 75 of HPV16 protein E6)
	AVCDKCLKF	(residues 68- 76 of HPV16 protein E6)

5 VCDKCLKFY (residues 69- 77 of HPV16 protein E6)  
 KISEYRHYC (residues 79- 87 of HPV16 protein E6)  
 ISEYRHYCY (residues 80- 88 of HPV16 protein E6)  
 LIRCINCQK (residues 107-115 of HPV16 protein E6)  
 5 TGRCMSCCR (residues 140-148 of HPV16 protein E6)  
 CMSCCRSSR (residues 143-151 of HPV16 protein E6)  
 SCCRSSRTR (residues 145-153 of HPV16 protein E6)  
 HYNIVTFCC (residues 51- 59 of HPV16 protein E7)  
 YNIVTFCKK (residues 52- 60 of HPV16 protein E7)  
 10 CCKCDSTLR (residues 58- 66 of HPV16 protein E7)  
 VCPICSQKP (residues 90- 98 of HPV16 protein E7), and  
 a fragment, homolog, isoform, derivative, genetic variant  
 or conservative variant of any one of these amino acid sequences  
 which has the ability to bind to human MHC Class I allele HLA-  
 15 A11.2.

According to another preferred embodiment of this invention,  
 said amino acid sequence has the ability to bind to human MHC  
 Class I allele HLA-A24.

20 More specifically, this invention provides a peptide  
 comprising an amino acid sequence derived from protein E6 or E7 of  
 HPV16, wherein said amino acid sequence has the ability to bind to  
 human MHC Class I allele HLA-A24 and is selected from the group  
 consisting of:

25 MHQKRTAMF (residues 1- 9 of HPV16 protein E6)  
 LQTTIHDII (residues 26- 34 of HPV16 protein E6)  
 VYCKQQLLR (residues 38- 46 of HPV16 protein E6)  
 LLRREVDYDF (residues 44- 52 of HPV16 protein E6)  
 VYDFAFRDL (residues 49- 57 of HPV16 protein E6)  
 PYAVCDKCL (residues 66- 74 of HPV16 protein E6)  
 30 KCLKFYSKI (residues 72- 80 of HPV16 protein E6)  
 EYRHYCYSL (residues 82- 90 of HPV16 protein E6)  
 HYCYSLYGT (residues 85- 93 of HPV16 protein E6)  
 CYSLYGTTL (residues 87- 95 of HPV16 protein E6)  
 RFHNIRGRW (residues 131-139 of HPV16 protein E6)  
 35 RAHYNIVTF (residues 49- 57 of HPV16 protein E7), and  
 a fragment, homolog, isoform, derivative, genetic variant

or conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A24.

5 This invention further provides a pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to the invention, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. Preferably, said pharmaceutical composition contains a peptide according to the invention which is able to induce a T cell response effective against HPV, in particular a HLA class I-restricted CD8<sup>+</sup> cytotoxic  
10 T cell response.

In addition, this invention provides a method of prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases with a human individual, comprising administering to said human individual a prophylactically or therapeutically  
15 effective amount of a peptide according to the invention, more specifically an immunogenic form of a peptide according to the invention which is able to induce a T cell response effective against HPV, in particular a HLA class I-restricted CD8<sup>+</sup> cytotoxic  
20 T cell response.

20

#### Brief description of the drawings

Figure 1 gives the result of binding analyses of 240 HPV16 E6 and E7 nonapeptides to HLA-A2.1 expressed on 174CEM.T2 cells.  
25 Background fluorescence level (without adding peptides) was set on an arbitrary mean fluorescence level of 70. Binding of a peptide was regarded positive when twice the level of background fluorescence was reached. The 18 binding peptides are numbered 1 to 18; this numbering corresponds to the numbering in Table I.

30 Figure 2 gives the result of binding analyses of 247 HPV18 E6 and E7 nonapeptides to HLA-A2.1 expressed on 174CEM.T2 cells. Background fluorescence level (without adding peptides) was set on an arbitrary mean fluorescence level of 70. Binding of a peptide was regarded positive when twice the level of background  
35 fluorescence was reached. The 14 binding peptides are numbered 1 to 14; this numbering corresponds to the numbering in Table II.

Figure 3 is a graph showing the primary CTL response of human lymphocytes from healthy donor blood against an HPV16 peptide (peptide MLDLQPETT, No. 13 in Table I, SEQ ID NO 15).

Bulk = bulk culture of CTL; clone = CTL clone from limiting  
5 dilution; irr. peptide = irrelevant peptide (control); and  
E/T ratio = effector target ratio.

#### Detailed description of the invention

10 The invention is directed to peptides comprising an amino acid sequence derived from a protein of HPV, wherein said amino acid sequence has the ability to bind to a human MHC Class I molecule. In view of our own experience with other viruses, the best candidates for induction of HLA class I restricted CD8<sup>+</sup>  
15 cytotoxic T cells are the strongest binding peptides.

A most preferred embodiment of the invention concerns peptides comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1. Specifically, such  
20 peptides comprise the following amino acid sequences derived from the noted regions of HPV16 (see Table I; the amino acids are identified by the one-letter code of amino acids).

TABLE I

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A2.1

5	Peptide	Amino acid	protein (region)	SEQ
	No.	sequence		ID NO
-----				
	-	AMFQDPQER	E6 (residues 7 - 15)	1
	1	KLPQLCTEL	E6 (residues 18 - 26)	2
	2	QLCTELQTT	E6 (residues 21 - 29)	3
10	3	LCTELQTTI	E6 (residues 22 - 30)	4
	4	ELQTTIHDI	E6 (residues 25 - 33)	5
	5	LQTTIHDI	E6 (residues 26 - 34)	6
	6	TIHDIILEC	E6 (residues 29 - 37)	7
	7	IHDIILECV	E6 (residues 30 - 38)	8
15	8	CVYCKQQLL	E6 (residues 37 - 45)	9
	-	FAFRDLCIV	E6 (residues 52 - 60)	10
	9	KISEYRHYC	E6 (residues 79 - 87)	11
	10	PLCDLLIRC	E6 (residues 102-110)	12
	11	TLHEYMLDL	E7 (residues 7 - 15)	13
20	12	YMLDLQPET	E7 (residues 11 - 19)	14
	13	MLDLQPETT	E7 (residues 12 - 20)	15
	14	RLCVQSTHV	E7 (residues 66 - 74)	16
	15	TLEDLLMGT	E7 (residues 78 - 86)	17
	16	LLMGTLGIV	E7 (residues 82 - 90)	18
25	17	GTLGIVCPI	E7 (residues 85 - 93)	19
	18	TLGIVCPIC	E7 (residues 86 - 94)	20

Another most preferred embodiment of the invention concerns peptides comprising an amino acid sequence derived from protein E6 or E7 of HPV18, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1. Specifically, such peptides comprise the following amino acid sequences derived from the noted regions of HPV18 (see Table II; the amino acids are identified by the one-letter code of amino acids).

TABLE II

Peptides derived from HPV18 proteins E6 and E7 binding to HLA-A2.1

Peptide No.	Amino acid sequence	protein (region)	SEQ ID NO
-----			
15	1	KLPDLCTEL	E6 (residues 13 - 21) 21
	2	SLQDIEITC	E6 (residues 24 - 32) 22
	3	LQDIEITCV	E6 (residues 25 - 33) 23
	4	EITCVYCKT	E6 (residues 29 - 37) 24
	5	KTVLELTEV	E6 (residues 36 - 44) 25
20	6	ELTEVFEFA	E6 (residues 40 - 48) 26
	7	FAFKDLFVV	E6 (residues 47 - 55) 27
	8	DTLEKLTNT	E6 (residues 88 - 96) 28
	9	LTNTGLYNL	E6 (residues 93 - 101) 29
	10	TLQDIVLHL	E7 (residues 7 - 15) 30
25	11	FQQLFLNTL	E7 (residues 86 - 94) 31
	12	QLFLNTLSF	E7 (residues 88 - 96) 32
	13	LFLNTLSFV	E7 (residues 89 - 97) 33
	14	LSFVCPWCA	E7 (residues 94 - 102) 34

Another preferred embodiment of the invention concerns peptides comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A1. Specifically, such peptides comprise the following amino acid sequences derived from the noted regions of HPV16 (see Table III; the amino acids are identified by the one-letter code of amino acids).

TABLE III

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A1

	Amino acid sequence	protein (region)	SEQ ID NO
-----			
15	YRDGNPYAV	E6 (residues 61- 69)	35
	WTGRCMSCC	E6 (residues 139-147)	36
	MSCCRSSRT	E6 (residues 144-152)	37
	TTDLICYEQ	E7 (residues 19- 27)	38
	EIDGPAGQA	E7 (residues 37- 45)	39
20	HVDIRTLED	E7 (residues 73- 81)	40

Another preferred embodiment of the invention concerns peptides comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A3.2. Specifically, such peptides comprise the following amino acid sequences derived from the noted regions of HPV16 (see Table IV; the amino acids are identified by the one-letter code of amino acids).

TABLE IV

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A3.2

5	Amino acid sequence	protein (region)	SEQ ID NO
	-----		
	AMFQDPQER	E6 (residues 7- 15)	1
	IILECVYCK	E6 (residues 33- 41)	41
	CVYCKQQLL	E6 (residues 37- 45)	9
10	VYCKQQLLR	E6 (residues 38- 46)	42
	QQLLRREVV	E6 (residues 42- 50)	43
	IVYRDGNPY	E6 (residues 59- 67)	44
	YAVCDKCLK	E6 (residues 67- 75)	45
	AVCDKCLKF	E6 (residues 68- 76)	46
15	VCDKCLKFY	E6 (residues 69- 77)	47
	KFYISKISEY	E6 (residues 75- 83)	48
	KISEYRHYC	E6 (residues 79- 87)	11
	ISEYRHYCY	E6 (residues 80- 88)	49
	RHYCYSLYG	E6 (residues 84- 92)	50
20	SLYGTITLEQ	E6 (residues 89- 97)	51
	TITLEQQYNK	E6 (residues 93-101)	52
	QQYNKPLCD	E6 (residues 97-105)	53
	LIRCINCQK	E6 (residues 107-115)	54
	HLDDKKQRFH	E6 (residues 125-133)	55
25	CMSCCRSSR	E6 (residues 143-151)	56
	SCCRSSRTR	E6 (residues 145-153)	57
	CCRSSRTRR	E6 (residues 146-154)	58
	HYNIIVTFCC	E7 (residues 51- 59)	59
	YNIIVTFCK	E7 (residues 52- 60)	60
30	CCKCDSTLR	E7 (residues 58- 66)	61
	KCDSTLRLC	E7 (residues 60- 68)	62

Another preferred embodiment of the invention concerns peptides comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A11.2. Specifically, such peptides comprise the following amino acid sequences derived from the noted regions of HPV16 (see Table V; the amino acids are identified by the one-letter code of amino acids).

TABLE V

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A11.2

	Amino acid sequence	protein (region)	SEQ ID NO
15	AMFQDPQER	E6 (residues 7- 15)	1
	IILECVYCK	E6 (residues 33- 41)	41
	CVYCKQQLL	E6 (residues 37- 45)	9
	VYCKQQLLR	E6 (residues 38- 46)	42
	QQLLRREVY	E6 (residues 42- 50)	43
20	IVYRDGNPY	E6 (residues 59- 67)	44
	YAVCDKCLK	E6 (residues 67- 75)	45
	AVCDKCLKF	E6 (residues 68- 76)	46
	VCDKCLKFY	E6 (residues 69- 77)	47
	KISEYRHYC	E6 (residues 79- 87)	11
25	ISEYRHYCY	E6 (residues 80- 88)	49
	LIRCINCQK	E6 (residues 107-115)	54
	TGRCMSSCR	E6 (residues 140-148)	63
	CMSSCRSSR	E6 (residues 143-151)	56
	SCCRSSRTR	E6 (residues 145-153)	57
30	HYNIVTFCC	E7 (residues 51- 59)	59
	YNIVTFCKK	E7 (residues 52- 60)	60
	CCKCDSTLR	E7 (residues 58- 66)	61
	VCPICSQKP	E7 (residues 90- 98)	64

Another preferred embodiment of the invention concerns peptides comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A24. Specifically, such peptides comprise the following amino acid sequences derived from the noted regions of HPV16 (see Table VI; the amino acids are identified by the one-letter code of amino acids).

TABLE VI

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A24

	Amino acid sequence	protein (region)	SEQ ID NO
15	MHQKRTAMF	E6 (residues 1- 9)	65
	LQTTIHDII	E6 (residues 26- 34)	6
	VYCKQQLLR	E6 (residues 38- 46)	42
	LLRREVDYDF	E6 (residues 44- 52)	66
	YDFAFRDL	E6 (residues 49- 57)	67
20	PYAVCDKCL	E6 (residues 66- 74)	68
	KCLKFYSKI	E6 (residues 72- 80)	69
	EYRHYCYSL	E6 (residues 82- 90)	70
	HYCYSLYGT	E6 (residues 85- 93)	71
	CYSLYGTTL	E6 (residues 87- 95)	72
25	RFHNIRGRW	E6 (residues 131-139)	73
	RAHYNIVTF	E7 (residues 49- 57)	74

The data suggest that the peptides mentioned above are single polypeptides of identified sequences. However, homologs, isoforms or genetic variants of these peptides may exist within or outside the cellular environment. This invention encompasses all such homologs, isoforms or genetic variants of the above peptides provided that they bind to the HLA molecule in question.

Polypeptides that are homologs of the peptides specifically include those having amino acid sequences which are at least about 40% conserved in relation to the amino acid sequence set forth in

Tables I-VI, preferentially at least about 60% conserved, and more preferentially at least about 75% conserved.

It will be understood by one of ordinary skill in the art that other variants of the peptides shown above are included within the scope of the present invention. This particularly includes any variants that differ from the above mentioned and synthesized peptides only by conservative amino acid substitution. In particular, replacements of C (cysteine) by A (alanine), S (serine),  $\alpha$ -aminobutyric acid and others are included as it is known that cysteine-containing peptides are susceptible to (air) oxidation during synthesis and handling. Many such conservative amino acid substitutions are set forth as sets by Taylor (1986).

Herein the peptides shown above or fragments thereof include any variation in the amino acid sequence, whether by conservative amino acid substitution, deletion, or other processes, provided that the polypeptides bind to the HLA molecule in question. The fragments of the peptides may be small peptides with sequences of as little as five or more amino acids, said sequences being those disclosed in Tables I-VI when said polypeptides bind to the HLA molecule in question.

Polypeptides larger than the peptides shown are especially included within the scope of the present invention when said polypeptides induce a HPV16- or HPV18-specific CTL response in appropriate individuals (e.g. HLA-A2.1 positive individuals in the case of HLA-A2.1 binding peptides) and include a (partial) amino acid sequence as set forth in Tables I-VI, or conservative substitutions thereof. Such polypeptides may have a length up to about 30 amino acids, preferably up to about 27 amino acids. Most preferably, however, the peptides have a length of from 9 to 12, more preferably 9 to 11 or even 9 to 10 amino acids, most of all preferably exactly 9 amino acids.

This invention includes the use of polypeptides generated by every means, whether genetic engineering, peptide synthesis with solid phase techniques or others. The foregoing peptides may have various chemical modifications made at the terminal ends and still be within the scope the present invention. Also other chemical

modifications are possible, particularly cyclic and dimeric configurations. The term "derivatives" intends to cover all such modified peptides.

5 The polypeptides of the present invention find utility for the treatment or prevention of diseases involving HPV16 or HPV18 such as genital warts, cervical cancer or others that are linked to HPV16 or HPV18.

10 For all applications the peptides are administered in an immunogenic form. Since the peptides are relatively short, this may necessitate conjugation with an immunogenicity conferring carrier material such as lipids or others or the use of adjuvants.

15 The magnitude of a prophylactic or a therapeutic dose of polypeptides of this invention will, of course, vary with the group of patients (age, sex, weight, etcetera), the nature of the severity of the condition to be treated, the particular polypeptide of this invention and its route of administration. Any suitable route of administration may be employed to achieve an effective dosage of a polypeptide identified by this invention, as well as any dosage form well known in the art of pharmacy. In  
20 addition the polypeptides may also be administered by controlled release means and/or delivery devices. They may also be administered in combination with other active substances, such as, in particular, T-cell activating agents like interleukine-2 etc.

25 The peptides of this invention may also be useful for other purposes, such as diagnostic use. For example, they may be used to check whether a vaccination with a peptide according to the invention has been successful. This may be done in vitro by testing whether said peptide is able to activate T cells of the vaccinated person.

30 The following examples illustrate the present invention without limiting the same thereto.

## EXAMPLE 1

Materials

Peptide synthesizer:

5 Abimed AMS 422 (Abimed Analysen-Technik GmbH, Langenfeld, Germany).

Synthesis polymer:

Tentagel S AC (0.17-0.24 meq/g, Rapp Polymere, Tübingen, Germany).

HPLC equipment:

10 The HPLC system used for analysis and purification of peptides consisted of: autosampler 2157, HPLC pump 2248, variable wavelength monitor VWM 2141, column oven 2155, low pressure mixer, all of Pharmacia Nederland B.V., Woerden, The Netherlands, a Star LC-20 dot matrix printer, Star Micronics Co., Ltd., all parts  
15 controlled by a Tandon PCAs1/386sx computer, Tandon Computer Benelux B.V., Amsterdam, The Netherlands.

Lyophilizer:

Virtis Centry, The Virtis Company, Inc., Gardiner (NY), USA, equipped with an Alcatel 350C vacuum pump, Alcatel CIT, Malakoff,  
20 France, connected to a Christ Alpha RVC vacuo-spin, Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany.

Centrifuge:

MSE Mistral 6L, Beun de Ronde, Abcoude, The Netherlands.

Mass spectrometer:

25 Bioion plasma desorption mass spectrometer (PDMS), Applied Biosystems, Inc., Foster City (CA), USA.

Amino acid Analysis:

HP Aminoquant, Hewlett Packard, Amstelveen, The Netherlands.

Chemicals:

30 All chemicals were used without further purification unless stated otherwise.

Fmoc (9-fluorenylmethyloxycarbonyl) amino acids were of the L-configuration, bearing the following side chain protecting groups: t-Bu (tert-butyl) for Asp, Glu, Tyr, Ser and Thr; Trt (trityl) for His, Asn and Gln; Pmc (2,2,5,7,8-pentamethylchroman-6-sulfonyl) for Arg; Boc (tert-butyloxycarbonyl) for Lys, all  
35

Novasyn and purchased from Pharmacia Nederland B.V., Woerden, The Netherlands.

Piperidine was purchased from Aldrich Chemie Benelux N.V., Brussels, Belgium.

5 BOP (benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate) was obtained from Richelieu Biotechnologies, St-Hyacinthe, Canada.

10 N-methylmorpholin (NMM, Janssen Chimica, Tilburg, The Netherlands) was distilled from NaOH at atmospheric pressure before use.

N-methylpyrrolidone (NMP, Aldrich Chemie) was vacuum-distilled under a nitrogen atmosphere (b.p. 78-80°C, 18 mm Hg) before use.

15 Acetonitrile (HPLC-grade) was purchased from Rathburn Chemicals Ltd., Walkerburn, Scotland.

Ether (Baker Analyzed grade), pentane (Baker grade) and acetic acid (Baker Analyzed grade) were purchased from J.T. Baker B.V., Deventer, The Netherlands.

20 Ethanethiol was obtained from Fluka Chemie, Brussels, Belgium.

Dichloromethane and N,N-dimethylacetamide (DMA) were purchased from Janssen Chimica, Tilburg, The Netherlands.

Trifluoroacetic acid (TFA, z.S. grade) was obtained from Merck-Schuchardt, Hohenbrunn, Germany.

25 Disposables:

Polypropylene reaction vessels containing a PTFE filter were purchased from Abimed Analysen-Technik GmbH, Langenfeld, Germany.

All other disposables used were made of polypropylene and obtained from Sarstedt B.V., Etten-Leur, The Netherlands.

30 Experimental conditions:

All experiments were performed at room temperature unless stated otherwise. All Fmoc protected aminoacids, synthesis polymers, peptides and TFA were stored at -20°C.

### Peptide synthesis

Peptides were synthesized by solid phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422) (see Gausepohl and Frank, 1990; Gausepohl et al., 1990).

5 The peptides were made in various runs, in each of which 48 different peptides were synthesized simultaneously.

Tentagel S AC (Rapp et al., 1990; Sheppard and Williams, 1982), a graft polymer of polyethyleneglycol spacer arms on a polystyrene matrix, was used as a resin (40-60 mg per peptide,  
10 10  $\mu$ mol Fmoc amino acid loading).

Repetitive couplings were performed by adding a mixture of 90  $\mu$ l 0.67 M BOP (Gausepohl et al., 1988; Castro et al., 1975) in NMP; 20  $\mu$ l NMM in NMP 2/1 (v/v) and 100  $\mu$ l of an 0.60 M solution of the appropriate Fmoc amino acid (Fields and Noble, 1990) in NMP  
15 (6-fold excess) to each reaction vessel. At 70% of the reaction time approximately 50  $\mu$ l dichloromethane was added to each reaction vessel.

Fmoc-deprotection was performed by adding 3 times 0.8 ml of piperidine/DMA 1/4 (v/v) to each reaction vessel.

20 Coupling- and deprotection times were increased as the synthesis proceeded, starting with 30 min and 3 times 3 min respectively.

Washings after couplings and Fmoc-deprotections were done with 6 times 1.2 ml DMA. After the required sequence had been  
25 reached and the last Fmoc-protection was removed the peptidylresin was washed extensively with DMA, dichloromethane, dichloromethane/ether 1/1 (v/v) and ether respectively, and dried.

### Peptide cleavage and isolation

30 Cleavage of the peptides from the resin and removal of the side chain protecting groups was performed by adding 6 times 200  $\mu$ l TFA/water 19/1 (v/v) at 5 min intervals to each reaction vessel, thus yielding free carboxylic peptides. For Trp-containing peptides TFA/water/ethanethiol 18/1/1 (v/v/v) was used.

35 Two hours after the first TFA addition the peptides were precipitated from the combined filtrates by addition of 10 ml

ether/pentane 1/1 (v/v) and cooling to -20°C. The peptides were isolated by centrifugation (-20°C, 2500g, 10 min).

After treatment of the pellet with ether/pentane 1/1 (v/v) and isolation by the same centrifugation procedure, the peptides were dried at 45°C for 15 min.

Each of the peptides was dissolved in 2 ml water (or 2 ml 10 vol.% acetic acid), the solution frozen in liquid nitrogen for 3 min, and lyophilized while being centrifuged (1300 rpm, 8-16 h).

#### 10 Analysis and purification

The purity of the peptides was determined by reversed phase HPLC; an aliquot of about 50 nmol was dissolved in 100 µl 30 vol.% acetic acid. Of this solution 30 µl was applied to an RP-HPLC system equipped with a ternary solvent system; A: water, B: acetonitrile, C: 2 vol.% TFA in water.

Gradient elution (1.0 ml/min) was performed from 90% A, 5% B, 5% C to 20% A, 75% B, 5% C in 30 min. Detection was at 214 nm.

Samples taken at random were analysed by mass spectrometry on a PDMS. The 31 binding peptides were all analysed by mass spectrometry on a PDMS and by quantitative amino acid analysis after hydrolysis on a HP Aminoquant. Of all analysed samples the difference between calculated and measured masses was within the experimental error (0.1%) as specified by the producer of the equipment used. All aminoacid compositions were as expected.

#### 25 EXAMPLE 2

##### Peptides

Of all 240 HPV16 peptides and 247 HPV18 peptides that had been freeze dried, 5 mg was weighed and dissolved in 1 ml of distilled water adjusted with 5N NaOH to a pH of 12. Peptides that did not readily dissolve were treated with 150 µl of 100% acetic acid glacial (CH<sub>3</sub>COOH, Merck Darmstadt, Germany: 56-1000) after which the pH was neutralized to pH7 with 5N NaOH diluted in distilled water (Merck Darmstadt, Germany: 6498). Peptides which still did not dissolve were treated with 100 µl of 5N NaOH to pH 12

after which the pH was neutralized to pH 7 with 10% acetic acid glacial in distilled water. Of all peptides a dilution of 1 mg/ml in 0.9% NaCl was made.

## 5 Cells

174CEM.T2 cells were cultured in Iscove's modified Dulbecco's medium (Biochrom KG Seromed Berlin, Germany: F0465) supplemented with 100IU/ml penicillin (Biocades Pharma, Leiderdorp, The Netherlands), 100 µg/ml kanamycin (Sigma St. Louis, USA:K-0254), 2mM glutamine (ICN Biomedicals Inc. Costa Mesa, CA, USA:15-801-55) and 10% fetal calf serum (FCS, Hyclone Laboratories Inc. Logan, Utah, USA:A-1115-L). Cells were cultured at a density of  $2.5 \times 10^5$ /ml during 3 days at 37°C, 5% CO<sub>2</sub> in humified air.

## 15 Peptide binding

174CEM.T2 cells were washed twice in culture medium without FCS and put in serum-free culture medium to a density of  $2 \times 10^6$  cells/ml. Of this suspension 40 µl was put into a V bottomed 96 well plate (Greiner GmbH, Frickenhausen, Germany: 651101) together with 10 µl of the individual peptide dilutions (of 1 mg/ml). The end concentration is 200 µg/ml peptide with  $8 \times 10^4$  174CEM.T2 cells. This solution was gently agitated for 3 minutes after which an incubation time of 16 hours at 37°C, 5% CO<sub>2</sub> in humified air took place. Then cells were washed once with 100 µl 0.9% NaCl, 0.5% bovine serum albumin (Sigma St. Louis, USA: A-7409), 0.02% NaN<sub>3</sub> (Merck Darmstadt, Germany:822335). After a centrifuge round of 1200 rpm the pellet was resuspended in 50 µl of saturating amounts of HLA-A2.1 specific mouse monoclonal antibody BB7.2 for 30 minutes at 4°C. Then cells were washed twice and incubated for 30 minutes with F(ab)<sub>2</sub> fragments of goat anti-mouse IgG that had been conjugated with fluoresceine isothiocyanate (Tago Inc Burlingame, CA, USA: 4350) in a dilution of 1:40 and a total volume of 25 µl.

After the last incubation, cells were washed twice and fluorescence was measured at 488 nanometer on a FACScan flow-cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The results

are shown in fig. 1 (HPV16 peptides) and fig. 2 (HPV18 peptides), respectively.

The 174CEM.T2 cell line expresses "empty" and unstable HLA-A2.1 molecules that can be stabilized when a peptide is binding to the peptide presenting groove of these molecules. A stabilized HLA-A2.1 molecule that will not easily degrade is the result of binding of an analyzed peptide. This leads to an increase in cell surface expression of the HLA-A2.1 molecule.

## 10 Results

In order to identify E6 and E7 region peptides of HPV16 and HPV18 that could bind to HLA-A2.1 molecules expressed by 174CEM.T2 cells, the amino acid sequences of E6 and E7 of HPV16 and HPV18 were examined (4). Every amino acid in the E6 and E7 region was used as the first amino acid of a 9 amino acid long peptide. In this way the entire E6 and E7 regions of HPV16 and HPV18 were covered. Nine amino acid long peptides were chosen because they fit the presently known rules for length of peptides that bind to the groove of HLA-A2.1 molecules (reviewed by Kast and Melief, 1991). For practical reasons, in a first series of experiments alanine residues were used in the tested peptides instead of the cysteine residues occurring in the natural sequence. Thereafter, a second series of experiments was carried out with peptides containing the cysteine residues of the natural sequence.

Only the peptides Nos. 1-18 of Table I and Nos. 1-14 of Table II (including those containing alanine residues instead of the cysteine residues) were able to significantly upregulate the expression of HLA-A2.1 molecules measured as mean HLA-A2.1 fluorescence of 174CEM.T2 cells indicating their binding to the HLA-A2.1 molecule as described in Example 2. None of the 222 + 233 other peptides were able to do this. The results of the fluorescence measurement are given in Tables VII and VIII and shown in Figures 1 and 2. The peptides are numbered in accordance with the numbering in Tables I and II.

MF = Mean Fluorescence

$$FI = \text{Fluorescence Index} = \frac{(MF)_{\text{experiment}} - (MF)_{\text{blank}}}{(MF)_{\text{blank}}}$$

5

With background fluorescence level (without adding peptides) set on a Fluorescence Index level of 0, binding of a peptide was regarded positive when the level of fluorescence was  $\geq 0.5$ .

10 TABLE VII: HPV16 peptides

	Peptide	FI	MF
	-----		-----
	1	1.6	168.6
15	2	2.2	211.9
	3	0.7	113.6
	4	0.6	108.0
	5	1.6	170.4
	6	1.8	184.5
20	7	1.3	150.7
	8	2.0	195.0
	9	2.2	211.7
	10	2.1	204.8
	11	1.2	144.5
25	12	3.3	283.9
	13	2.3	217.6
	14	2.8	250.0
	15	1.8	182.8
	16	0.8	118.8
30	17	2.3	216.1
	18	2.5	227.8

TABLE VIII: HPV18 peptides

	Peptide	FI	MF
-----			
5	1	2.1	439.3
	2	0.7	243.9
	3	1.3	327.8
	4	0.5	206.0
	5	2.3	467.5
10	6	1.1	289.0
	7	2.3	462.9
	8	0.7	238.2
	9	1.5	352.5
	10	2.7	519.6
15	11	0.8	244.5
	12	0.8	258.2
	13	1.6	360.3
	14	0.9	262.0

20        These experiments indicate that only a limited proportion of peptides have the ability to bind to the HLA-A2.1 molecule and are therefore the only candidates of the HPV16 and HPV18 E regions to be recognized by human CTL because CTL recognize peptides only when bound to HLA molecules.

### 25        EXAMPLE 3

30        This example illustrates in vitro induction of primary immune response against HPV peptides using the processing defective cell line 174CEM.T2.

35        The expression of HLA-A2.1 on 174CEM.T2 cells (T2) is increased by incubating T2 cells in medium containing relevant peptide. T2 cells will present the relevant peptide bound to HLA-A2.1 in high amount and therefore are good antigen presenting cells (APC). In the response inducing

method described below the T2 cell line is used as APC and post-Ficoll mononuclear cells are used as responder cells.

#### Method

- 5 1) Peptide loading of HLA-A2.1 on T2  
T2 cells in a concentration of  $2 \times 10^6$  cells per ml were incubated for 13 h at 37°C in a T 25 flask (Becton Dickinson, Falcon, Plymouth Engeland cat.nr. 3013) in serum-free IMDM (= Iscoves Modified Dulbecco's Medium: Biochrom KG, Seromed  
10 Berlin, Germany, cat.nr. F0465) with glutamine (2mM, ICN Biochemicals Inc., Costa Meisa, USA, cat.nr. 15-801-55), antibiotics (100 IU/ml penicilline (Brocades Pharma, Leiderdorp, The Netherlands, 100 µg/ml kanamycine (Sigma, St. Louis, USA, K-0245)) and the selected peptide MLDLQPETT  
15 (= JWK3; SEQ ID NO:15) in a concentration of 80 µg/ml.
- 2) Mitomycine C treatment of T2 (APC)  
These incubated T2 cells were spun down and subsequently treated in a density of  $20 \times 10^6$  cells/ml with Mitomycine C  
20 (50µg/ml) in serum-free RPMI (Gibco Paislan, Scotland, cat.nr. 041-02409) medium for 1 h at 37°C. Hereafter the T2 cells were washed three times in RPMI.
- 3) Preparing for primary immune response induction  
25 All wells of a 96-well-U-bottom plate (Costar, Cambridge, USA, cat.nr. 3799) were filled with 100,000 Mitomycine C-treated T2 cells in 50µl serum-free, complete RPMI medium (glutamine (2mM, ICN Biochemicals Inc., Costa Meisa, USA, cat.nr. 15-801-55), penicilline (100 IU/ml, Brocades Pharma, Leiderdorp, The Netherlands), kanamycine  
30 (100µg/ml, Sigma, St. Louis, USA, K-0245)) and the peptide MLDLQPETT in a concentration of 80 µg/ml.
- 4) Responder cells  
35 Responder cells are mononuclear peripheral blood lymphocytes (PBL) of a HLA-A2.1 subtyped donor (= C.B.). The

PBL were separated from a buffy coat by Ficoll-procedure (Ficoll preparation: Lymphoprep of Nycomed-pharma, Oslo, Norway, cat.nr. 105033) and washed two times in RPMI. After separation and washing, the PBL were resuspended in complete RPMI medium with 30% human pooled serum (HPS) (HPS is tested for suppression activity in Mixed Lymphocyte Cultures).

5) Incubation of primary immune response

400,000 PBL-C.B. in 50µl of medium (the medium described in header 4) were added to each well of the 96-well-U-bottom plate already filled with T2 cells and cultured for 7 days at 37°C in an incubator with 5% CO<sub>2</sub> and 90% humidity.

6) Restimulation (day 7)

On day 7 after incubation of PBL, peptide MLDLQPETT and T2 cells (headers 1-5), the PBL-C.B. were restimulated with peptide MLDLQPETT. For this purpose all cells and medium out of the 96 wells were harvested. Viable cells were isolated by Ficoll-procedure and washed in RPMI. In a new 96-well-U-bottom plate 50,000 of these viable cells were seeded to each well together with 50µl complete RPMI medium with 15% HPS. Per well 20,000 autologous, irradiated (3000 rad) PBL and 50,000 autologous, irradiated (10000 rad) EBV-transformed B-lymphocytes (= EBV-C.B.) were added together with 50µl of complete RPMI medium with 15% HPS and peptide MLDLQPETT in a concentration of 80µg/ml. The cells were cultured for 7 days at 37°C in an incubator with 5% CO<sub>2</sub> and 90% humidity.

7) Restimulation (day 14)

On day 14 after incubation of PBL, peptide MLDLQPETT and T2 cells (headers 1-5), the PBL-C.B. were restimulated with peptide MLDLQPETT. To do so the procedure under header 6 is repeated.

## 8) Cloning by Limiting Dilution

On day 21 after incubation of PBL, peptide MLDLQPETT and T2 cells, cells and medium out of the 96 wells were harvested. Viable cells were isolated by Ficoll-procedure and washed in complete RPMI with 15% HPS. This bulk of viable cells was cloned by Limiting Dilution. Into each well of a new 96-well-U-bottom plate (Costar, Cambridge, USA, cat. nr. 3799) 50µl complete RPMI medium with 15 % HPS was added together with 100 viable cells (= HPV16 bulk anti MLDLQPETT). For other new 96-well-U-bottom plates this was exactly repeated except for the number of cells for wells: subsequent plates contained 10, 1, or 0.3 cells per well. To all wells 20,000 pooled and irradiated (3000 rad) PBL of four different donors and 10,000 pooled and irradiated (10,000 rad) EBV-transformed B-cells of three different HLA-A2.1 donors (VU-4/518/JY) were added together with 50µl of complete RPMI medium with 15% HPS and peptide MLDLQPETT in a concentration of 40µg/ml, Leucoagglutinin in a concentration of 2% (Pharmacia, Uppsala, Sweden, cat.nr. 17-063-01), human recombinant IL-2 in a concentration of 120 IU/ml (Eurocetus, Amsterdam, The Netherlands).

## 9) Expand clones

Add per well, in a final volume of 100 µl =>

- 25,000 viable cells
- 20,000 irradiated PBL-pool (as in header 8)
- 10,000 irradiated EBV-pool (as in header 8)
- 2 µg peptide MLDLQPETT
- 6 IU recombinant IL-2.

On day 49 a cytotoxicity assay was performed with 65 clones and one bulk as effector cells and T2 (with or without the relevant peptide MLDLQPETT) as target cells. Background killing is defined as killing of T2 cells incubated with an irrelevant (but HLA-A2.1 binding) peptide: ATELQTTIH.

The HPV16 bulk (C.B.) anti MLDLQPETT seemed to be specific for killing MLDLQPETT-sensitized T2 cells. All the clones were not specific.

5 A new limiting dilution was done with the HPV16 bulk (C.B.) anti MLDLQPETT cells (as in header 8+9).

On day 28 after the new limiting dilution a cytotoxicity assay was performed with five clones (ID10, ID12, ID19, ID26, ID92) and one bulk. A representative clone is shown in fig. 3.

#### 10 EXAMPLE 4

This example illustrates an immunochemical peptide-MHC binding assay which was used to determine which HPV16 protein E6 and E7 peptides bind to HLA-A1, A2.1, A3.2, A11.2 and A24  
15 molecules.

The method utilizes purified class I molecules and radiolabeled synthetic probes based on consensus peptides. Competitor peptides tested for their binding to the class I molecules compete for this binding with the radiolabeled  
20 consensus peptides. The HLA-A1, A2.1, A3.2, A11.2, and A24 molecules were isolated from the following cell lines, respectively: the EBV (Eppstein Barr Virus) transformed cell line Steinlin, the EBV transformed cell line JY, the EBV transformed cell line GM3107, the cell line BVR and the EBV  
25 transformed cell line KT3. After large scale culture, cells were lysed in NP40 (Fluka Biochemika, Buchs, Switzerland) and the lysate was passed over two pre-columns of inactivated sepharose CL 4B and Prot A Sepharose. Class I molecules were then purified from the cell lysate by affinity chromatography  
30 using Prot A Sepharose beads conjugated with B2.23.2 (anti-HLA-B and HLA-C) and anti-human HLA. The lysate was first depleted of B and C molecules by repeated passage over the B2.23.2 column. Remaining HLA-A molecules were then captured by the W6/32 column and eluted by pH 11.5 DEA/1% OG  
35 neutralized with 1 mM Tris pH 6.8 and concentrated by ultrafiltration on Amicon 30 K<sub>D</sub> cartridges.

For binding assays, MHC amounts that resulted in binding of 15% of the radiolabeled synthetic probes (normally in the 10-50 nM range) were incubated in 0.05% NP40-PBS with about 5 nM of radiolabeled peptides and titrated amounts of unlabeled competitor peptides to be tested (usually in the 10 mg to 1 ng/ml range) in the presence of 1  $\mu$ M  $\beta$ 2M and a cocktail of protease inhibitors (with final concentrations of 1 mM PMSF, 1.3 mM 1,10-Phenanthroline, 73  $\mu$ M Pepstatin A, 8 mM EDTA, 200  $\mu$ M N- $\alpha$ -p-tosyl-L-Lysine Chloromethyl ketone). After two days at 23°C the percent of MHC-bound radioactivity was measured by size exclusion chromatography on a TSK2000 gel filtration as described by Sette et al. (1992).

Probe peptides were iodinated by using the Chloramine T method described by Buus et al. (1987). The sequences of the probe peptides used for the aforementioned HLA molecules were YLEPAIAKY for A1, FLPSDYFPSV for A2.1, KVFPYALINK for A3.2, AVDLYHFLK for A11.2, and AYIDNYNKF for A24.

To allow comparison of the data obtained in different experiments, a relative binding figure was calculated for each peptide by dividing the 50% inhibition dose (IC<sub>50</sub>) for the positive control for inhibition of unlabeled probe peptides by the 50% inhibition doses for each tested peptide. The values of the 50% inhibition dose for the probes was: 81 nM for A1, 5 nM for A2.1, 30 nM for A3.2, 9 nM for A11.2 and 22 nM for A24.

Each competitor peptide was tested in two to four completely independent experiments. Since cysteine containing peptides are susceptible to (air) oxidation during synthesis and handling, these peptides were synthesized with an alanine instead of a cysteine. Arbitrarily, the competitor peptides were categorized as good binders, intermediate binders, weak binders and negative binders when they fell into the following ratio categories: 1.0-0.1, 0.1-0.01, 0.01-0.001, and < 0.001, respectively.

The results are shown in Tables IX to XIII.

TABLE IX: HPV16 E6 and E7 peptides binding to HLA-A1 in immunochemical assay

5	Peptide	protein (region)	SEQ ID NO	binding ratio to standard#
	-----			
	YRDGNPYAV	E6 (residues 61- 69)	35	0.008
	WTGRCMSCC	E6 (residues 139-147)	36	0.020
	MSCCRSSRT	E6 (residues 144-152)	37	0.019
10	TTDLICYEQ	E7 (residues 19- 27)	38	0.023
	EIDGPAGQA	E7 (residues 37- 45)	39	0.025
	HVDIRTLED	E7 (residues 73- 81)	40	0.014

# The average IC<sub>50</sub> value  $\pm$ SE of the standard in the course of  
15 the experiments considered in this table was 81  $\pm$ 30 nM.

TABLE X: Additional HPV16 E6 and E7 peptides binding to HLA-A2.1 in immunochemical assay

20	Peptide	protein (region)	SEQ ID NO	binding ratio to standard#
	-----			
	AMFQDPQER	E6 (residues 7- 15)	1	0.0033
	FAFRDLCIV	E6 (residues 52- 60)	10	0.3700

25

# The average IC<sub>50</sub> value  $\pm$ SE of the standard in the course of  
the experiments considered in this table was 6  $\pm$ 1 nM.

TABLE XI: HPV16 E6 and E7 peptides binding to HLA-A3.2 in immunochemical assay

	Peptide	protein (region)	SEQ ID NO	binding ratio to standard#
5	-----	-----	-----	-----
	AMFQDPQER	E6 (residues 7- 15)	1	0.1000
	IILECVYCK	E6 (residues 33- 41)	41	1.5000
	CVYCKQQLL	E6 (residues 37- 45)	9	0.0320
10	VYCKQQLLR	E6 (residues 38- 46)	42	0.0012
	QQLLRREVY	E6 (residues 42- 50)	43	0.0058
	IVYRDGNPY	E6 (residues 59- 67)	44	3.0000
	YAVCDKCLK	E6 (residues 67- 75)	45	0.0012
	AVCDKCLKF	E6 (residues 68- 76)	46	0.0056
15	VCDKCLKFY	E6 (residues 69- 77)	47	0.0025
	KFYISKISEY	E6 (residues 75- 83)	48	0.0100
	KISEYRHYC	E6 (residues 79- 87)	11	0.0044
	ISEYRHYCY	E6 (residues 80- 88)	49	0.0064
	RHYCYSLYG	E6 (residues 84- 92)	50	0.0036
20	SLYGTITLEQ	E6 (residues 89- 97)	51	0.0080
	TTLEQQYNK	E6 (residues 93-101)	52	0.0780
	QQYNKPLCD	E6 (residues 97-105)	53	0.0045
	LIRCINCQK	E6 (residues 107-115)	54	3.7000
	HLDKKQRFH	E6 (residues 125-133)	55	0.4400
25	CMSCCRSSR	E6 (residues 143-151)	56	0.1800
	SCCRSSRTR	E6 (residues 145-153)	57	0.0200
	CCRSSRTRR	E6 (residues 146-154)	58	0.0020
	HYNIIVTFCC	E7 (residues 51- 59)	59	0.0260
	YNIIVTFCK	E7 (residues 52- 60)	60	0.0067
30	CCKCDSTLR	E7 (residues 58- 66)	61	0.0016
	KCDSTLRLC	E7 (residues 60- 68)	62	0.0012

# The average IC<sub>50</sub> value  $\pm$ SE of the standard in the course of the experiments considered in this table was 30  $\pm$ 3 nM.

TABLE XII: HPV16 E6 and E7 peptides binding to HLA-A11.2 in immunochemical assay

	Peptide	protein (region)	SEQ ID NO	binding ratio to standard#
5	-----	-----	-----	-----
	AMFQDPQER	E6 (residues 7- 15)	1	0.8400
	IILECVYCK	E6 (residues 33- 41)	41	6.7000
	CVYCKQQLL	E6 (residues 37- 45)	9	0.0450
10	VYCKQQLLR	E6 (residues 38- 46)	42	0.0022
	QQLLRREVV	E6 (residues 42- 50)	43	0.0084
	IVYRDGNPY	E6 (residues 59- 67)	44	0.4700
	YAVCDKCLK	E6 (residues 67- 75)	45	0.0074
	AVCDKCLKF	E6 (residues 68- 76)	46	0.0037
15	VCDKCLKFY	E6 (residues 69- 77)	47	0.0030
	KISEYRHYC	E6 (residues 79- 87)	11	0.0076
	ISEYRHYCY	E6 (residues 80- 88)	49	0.4300
	LIRCINCQK	E6 (residues 107-115)	54	0.0120
	TGRCMSCCR	E6 (residues 140-148)	63	0.0012
20	CMSSCRSSR	E6 (residues 143-151)	56	0.0084
	SSCRSSRTR	E6 (residues 145-153)	57	0.0330
	HYNIVTFCC	E7 (residues 51- 59)	59	0.0010
	YNIVTFCKK	E7 (residues 52- 60)	60	0.0060
	CCKCDSTLR	E7 (residues 58- 66)	61	0.0110
25	VCPICSQKP	E7 (residues 90- 98)	64	0.0012

# The average  $IC_{50}$  value  $\pm$ SE of the standard in the course of the experiments considered in this table was  $10 \pm 3$  nM.

TABLE XIII: HPV16 E6 and E7 peptides binding to HLA-A24 in immunochemical assay

	Peptide	protein (region)	SEQ ID NO	binding ratio to standard#
5	-----	-----	-----	-----
	MHQKRTAMF	E6 (residues 1- 9)	65	0.0049
	LQTTIHDII	E6 (residues 26- 34)	6	0.0200
	VYCKQQLLR	E6 (residues 38- 46)	42	0.0011
10	LLRREVYDF	E6 (residues 44- 52)	66	0.0023
	VYDFAFRDL	E6 (residues 49- 57)	67	0.0610
	PYAVCDKCL	E6 (residues 66- 74)	68	0.0055
	KCLKFYSKI	E6 (residues 72- 80)	69	0.1100
	EYRHYCYSL	E6 (residues 82- 90)	70	0.0460
15	HYCYSLYGT	E6 (residues 85- 93)	71	0.0037
	CYSLYGTTL	E6 (residues 87- 95)	72	0.1200
	RFHNIRGRW	E6 (residues 131-139)	73	0.1000
	RAHYNIVTF	E7 (residues 49- 57)	74	0.0670

20 # The average IC<sub>50</sub> value  $\pm$ SE of the standard in the course of the experiments considered in this table was 22  $\pm$ 6 nM.

References:

1. W.M. Kast and C.J.M. Melief. In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. *Immunology Letters* 30: 229-232 (1991)
2. G. Reinholdsson-Ljunggren, T. Ramqvist, L. Åhrlund-Richter and T. Dalianis. *Int. J. Cancer* 50: 142-146 (1992)
3. R.D. Salter and P. Cresswell. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. *EMBO J.* 5: 943-949 (1986)
4. K. Seedorf, G. Krämer, M. Dürst, S. Suhai and W.G. Röwekamp. Human Papillomavirus Type 16 DNA Sequence. *Virology* 145: 181-185 (1985)
5. W.R. Taylor. Identification of Protein Sequence Homology by Consensus Template Alignment. *J. Mol. Biol.* 188: 233-258 (1986)
6. H. Gausepohl and R.W. Frank. Automatische multiple Peptidsynthese. *BioTec* (September 1990)
7. H. Gausepohl, M. Kraft, C. Boulin and R.W. Frank. in: E. Giralt and D. Andreu (eds). *Peptides 1990*, 206-207 (1990)
8. W. Rapp, L. Zhang and E. Bayer. Continuous flow peptide synthesis on PSPOE-Graft-copolymers. In: *Innovation and Perspectives in Solid Phase Peptide Synthesis*, 205-210 (1990)
9. R.C. Sheppard and B.J. Williams. Acid-labile resin linkage agents for use in solid phase peptide synthesis. *Int. J. Peptide Protein Res.* 20, 451-454 (1982)
10. H. Gausepohl, M. Kraft and R. Frank. In situ activation of Fmoc-amino acids by BOP in solid phase peptide synthesis. *Peptides* 1988, 241-243 (1988)
11. B. Castro, J.R. Dormoy, G. Evin and C. Selve. Reactifs de couplage peptidique IV (1)-L'hexafluorophosphate de benzotriazolyl N-oxytrisdiméthylamino phosphonium (B.O.P.). *Tetrahedron Letters* 14: 1219-1222 (1975)
12. G.B. Fields and R.L. Noble. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. *Int. J. Peptide Protein Res.* 35: 161-214 (1990)

13. A. Sette, S. Southwood, D. O'Sullivan, F.C. Gaeta, J. Sidney and H.M. Grey. Effect of pH on MHC class II-peptide interactions. J. Immunol. 148: 844 (1992)
14. S. Buus, A. Sette, S.M. Colon, C. Miles and H.M. Grey. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 235: 1352 (1987)

## SEQUENCE LISTING

SEQ ID NO:1

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

AlaMetPheGlnAspProGlnGluArg  
1 5 9

SEQ ID NO:2

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LysLeuProGlnLeuCysThrGluLeu  
1 5 9

SEQ ID NO:3

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GlnLeuCysThrGluLeuGlnThrThr  
1 5 9

SEQ ID NO:4

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuCysThrGluLeuGlnThrThrIle  
1 5 9

SEQ ID NO:5

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GluLeuGlnThrThrIleHisAspIle  
1 5 9

SEQ ID NO:6

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuGlnThrThrIleHisAspIleIle  
1 5 9

SEQ ID NO:7

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrIleHisAspIleIleLeuGluCys  
1 5 9

SEQ ID NO:8

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

IleHisAspIleIleLeuGluCysVal  
1 5 9

SEQ ID NO:9

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

CysValTyrCysLysGlnGlnLeuLeu  
1 5 9

SEQ ID NO:10

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

PheAlaPheArgAspLeuCysIleVal  
1 5 9

SEQ ID NO:11

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LysIleSerGluTyrArgHisTyrCys  
1 5 9

SEQ ID NO:12

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ProLeuCysAspLeuLeuIleArgCys  
1 5 9

SEQ ID NO:13

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrLeuHisGluTyrMetLeuAspLeu  
1 5 9

SEQ ID NO:14

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

TyrMetLeuAspLeuGlnProGluThr  
1 5 9

SEQ ID NO:15

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

MetLeuAspLeuGlnProGluThrThr  
1 5 9

SEQ ID NO:16

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ArgLeuCysValGlnSerThrHisVal  
1 5 9

SEQ ID NO:17

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrLeuGluAspLeuLeuMetGlyThr  
1 5 9

SEQ ID NO:18

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuLeuMetGlyThrLeuGlyIleVal  
1 5 9

SEQ ID NO:19

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GlyThrLeuGlyIleValCysProIle  
1 5 9

SEQ ID NO:20

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrLeuGlyIleValAlaProIleCys  
1 5 9

SEQ ID NO:21

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LysLeuProAspLeuCysThrGluLeu  
1 5 9

SEQ ID NO:22

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

SerLeuGlnAspIleGluIleThrCys  
1 5 9

SEQ ID NO:23

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuGlnAspIleGluIleThrCysVal  
1 5 9

SEQ ID NO:24

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GluIleThrCysValTyrCysLysThr  
1 5 9

SEQ ID NO:25

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LysThrValLeuGluLeuThrGluVal  
1 5 9

SEQ ID NO:26

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GluLeuThrGluValPheGluPheAla  
1 5 9

SEQ ID NO:27

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

PheAlaPheLysAspLeuPheValVal  
1 5 9

SEQ ID NO:28

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

AspThrLeuGluLysLeuThrAsnThr  
1 5 9

SEQ ID NO:29

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuThrAsnThrGlyLeuTyrAsnLeu  
1 5 9

SEQ ID NO:30

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrLeuGlnAspIleValLeuHisLeu  
1 5 9

SEQ ID NO:31

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

PheGlnGlnLeuPheLeuAsnThrLeu  
1 5 9

SEQ ID NO:32

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GlnLeuPheLeuAsnThrLeuSerPhe  
1 5 9

SEQ ID NO:33

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuPheLeuAsnThrLeuSerPheVal  
1 5 9

SEQ ID NO:34

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuSerPheValCysProTrpCysAla  
1 5 9

SEQ ID NO:35

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

TyrArgAspGlyAsnProTyrAlaVal  
1 5 9

SEQ ID NO:36

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

TrpThrGlyArgCysMetSerCysCys  
1 5 9

SEQ ID NO:37

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

MetSerCysCysArgSerSerArgThr  
1 5 9

SEQ ID NO:38

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrThrAspLeuTyrCysTyrGluGln  
1 5 9

SEQ ID NO:39

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GluIleAspGlyProAlaGlyGlnAla  
1 5 9

SEQ ID NO:40

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

HisValAspIleArgThrLeuGluAsp  
1 5 9

SEQ ID NO:41

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

IleIleLeuGluCysValTyrCysLys  
1 5 9

SEQ ID NO:42

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ValTyrCysLysGlnGlnLeuLeuArg  
1 5 9

SEQ ID NO:43

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GlnGlnLeuLeuArgArgGluValTyr  
1 5 9

SEQ ID NO:44

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

IleValTyrArgAspGlyAsnProTyr  
1 5 9

SEQ ID NO:45

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

TyrAlaValCysAspLysCysLeuLys  
1 5 9

SEQ ID NO:46

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

AlaValCysAspLysCysLeuLysPhe  
1 5 9

SEQ ID NO:47

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ValCysAspLysCysLeuLysPheTyr  
1 5 9

SEQ ID NO:48

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LysPheTyrSerLysIleSerGluTyr  
1 5 9

SEQ ID NO:49

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

IleSerGluTyrArgHisTyrCysTyr  
1 5 9

SEQ ID NO:50

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ArgHisTyrCysTyrSerLeuTyrGly  
1 5 9

SEQ ID NO:51

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

SerLeuTyrGlyThrThrLeuGluGln  
1 5 9

SEQ ID NO:52

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrThrLeuGluGlnGlnTyrAsnLys  
1 5 9

SEQ ID NO:53

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GlnGlnTyrAsnLysProLeuCysAsp  
1 5 9

SEQ ID NO:54

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuIleArgCysIleAsnCysGlnLys  
1 5 9

SEQ ID NO:55

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

HisLeuAspLysLysGlnArgPheHis  
1 5 9

SEQ ID NO:56

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

CysMetSerCysCysArgSerSerArg  
1 5 9

SEQ ID NO:57

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

SerCysCysArgSerSerArgThrArg  
1 5 9

SEQ ID NO:58

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

CysCysArgSerSerArgThrArgArg  
1 5 9

SEQ ID NO:59

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

HisTyrAsnIleValThrPheCysCys  
1 5 9

SEQ ID NO:60

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

TyrAsnIleValThrPheCysCysLys  
1 5 9

SEQ ID NO:61

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

CysCysLysCysAspSerThrLeuArg  
1 5 9

SEQ ID NO:62

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LysCysAspSerThrLeuArgLeuCys  
1 5 9

SEQ ID NO:63

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ThrGlyArgCysMetSerCysCysArg  
1 5 9

SEQ ID NO:64

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ValCysProIleCysSerGlnLysPro  
1 5 9

SEQ ID NO:65

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

MethHisGlnLysArgThrAlaMetPhe  
1 5 9

SEQ ID NO:66

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LeuLeuArgArgGluValTyrAspPhe  
1 5 9

SEQ ID NO:67

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ValTyrAspPheAlaPheArgAspLeu

1 5 9

SEQ ID NO:68

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

PheTyrAlaValCysAspLysCysLeu

1 5 9

SEQ ID NO:69

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

LysCysLeuLysPheTyrSerLysIle

1 5 9

SEQ ID NO:70

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

GluTyrArgHisTyrCysTyrSerLeu

1 5 9

SEQ ID NO:71

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

HisTyrCysTyrSerLeuTyrGlyThr

1 5 9

SEQ ID NO:72

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

CysTyrSerLeuTyrGlyThrThrLeu

1 5 9

SEQ ID NO:73

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ArgPheHisAsnIleArgGlyArgTrp

1 5 9

SEQ ID NO:74

SEQUENCE TYPE: amino acid

SEQUENCE LENGTH: 9 amino acids

ArgAlaHisTyrAsnIleValThrPhe

1 5 9

## CLAIMS

1. A peptide comprising an amino acid sequence derived from a protein of human papilloma virus (HPV), wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex (MHC) Class I molecule.

2. A peptide according to claim 1, wherein said amino acid sequence is derived from protein E6 or E7 of HPV16.

3. A peptide according to claim 1, wherein said amino acid sequence is derived from protein E6 or E7 of HPV18.

4. A peptide according to claim 1 or claim 2 or claim 3, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.

5. A peptide according to claim 1, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

	AMFQDPQER	(residues 7- 15 of HPV16 protein E6)
	KLPQLCTEL	(residues 18- 26 of HPV16 protein E6)
	QLCTELQTT	(residues 21- 29 of HPV16 protein E6)
	LCTELQTTI	(residues 22- 30 of HPV16 protein E6)
20	ELQTTIHDI	(residues 25- 33 of HPV16 protein E6)
	LQTTIHDI	(residues 26- 34 of HPV16 protein E6)
	TIHDIILEC	(residues 29- 37 of HPV16 protein E6)
	IHDIILECV	(residues 30- 38 of HPV16 protein E6)
	CVYCKQQLL	(residues 37- 45 of HPV16 protein E6)
25	FAFRDLCIV	(residues 52- 60 of HPV16 protein E6)
	KISEYRHYC	(residues 79- 87 of HPV16 protein E6)
	PLCDLLIRC	(residues 102-110 of HPV16 protein E6)
	TLHEYMLDL	(residues 7- 15 of HPV16 protein E7)
	YMLDLQPET	(residues 11- 19 of HPV16 protein E7)
30	MLDLQPETT	(residues 12- 20 of HPV16 protein E7)
	RLCVQSTHV	(residues 66- 74 of HPV16 protein E7)
	TLEDLLMGT	(residues 78- 86 of HPV16 protein E7)
	LLMGTLGIV	(residues 82- 90 of HPV16 protein E7)

GTLGIVCPI (residues 85- 93 of HPV16 protein E7)  
 TLGIVCPIC (residues 86- 94 of HPV16 protein E7), and  
 a fragment, homolog, isoform, derivative, genetic variant  
 or conservative variant of any one of these amino acid sequences  
 5 which has the ability to bind to human MHC Class I allele HLA-  
 A2.1.

6. A peptide according to claim 1, comprising an amino acid  
 sequence derived from protein E6 or E7 of HPV18, wherein said  
 amino acid sequence has the ability to bind to human MHC Class I  
 10 allele HLA-A2.1 and is selected from the group consisting of:

KLPDLCTEL (residues 13- 21 of HPV18 protein E6)  
 SLQDIEITC (residues 24- 32 of HPV18 protein E6)  
 LQDIEITCV (residues 25- 33 of HPV18 protein E6)  
 EITCVYCKT (residues 29- 37 of HPV18 protein E6)  
 15 KTVLELTEV (residues 36- 44 of HPV18 protein E6)  
 6, 5, 2, 2  
 9, 7, 5, 3, 1 ELTEVFEFA (residues 40- 48 of HPV18 protein E6)  
FAFKDLFVV (residues 47- 55 of HPV18 protein E6)  
 DTLEKLTNT (residues 88- 96 of HPV18 protein E6)  
 LTNTGLYNL (residues 93-101 of HPV18 protein E6)  
 20 TLQDIVLHL (residues 7- 15 of HPV18 protein E7)  
 FQQLFLNLT (residues 86- 94 of HPV18 protein E7)  
 QLFLNLTLSF (residues 88- 96 of HPV18 protein E7)  
 LFLNLTLSFV (residues 89- 97 of HPV18 protein E7)  
 LSFVCPWCA (residues 94-102 of HPV18 protein E7), and  
 25 a fragment, homolog, isoform, derivative, genetic  
 variant or conservative variant of any one of these amino acid  
 sequences which has the ability to bind to human MHC Class I  
 allele HLA-A2.1.

7. A peptide according to claim 1, wherein said amino acid  
 30 sequence has the ability to bind to human MHC Class I allele HLA-  
 A1.

8. A peptide according to claim 1, comprising an amino acid  
 sequence derived from protein E6 or E7 of HPV16, wherein said  
 amino acid sequence has the ability to bind to human MHC Class I  
 35 allele HLA-A1 and is selected from the group consisting of:

YRDGNPYAV (residues 61- 69 of HPV16 protein E6)

WTGRCMSCC (residues 139-147 of HPV16 protein E6)

MSCCRSSRT (residues 144-152 of HPV16 protein E6)

TTDLICYEQ (residues 19- 27 of HPV16 protein E7)

10 EIDGPAGQA (residues 37- 45 of HPV16 protein E7)

5 HVDIRTLED (residues 73- 81 of HPV16 protein E7), and  
a fragment, homolog, isoform, derivative, genetic  
variant or conservative variant of any one of these amino acid  
sequences which has the ability to bind to human MHC Class I  
allele HLA-A1.

10 9. A peptide according to claim 1, wherein said amino acid  
sequence has the ability to bind to human MHC Class I allele HLA-  
A3.2.

10. A peptide according to claim 1, comprising an amino acid  
sequence derived from protein E6 or E7 of HPV16, wherein said  
15 amino acid sequence has the ability to bind to human MHC Class I  
allele HLA-A3.2 and is selected from the group consisting of:

AMFQDPQER (residues 7- 15 of HPV16 protein E6)

IILECVYCK (residues 33- 41 of HPV16 protein E6)

CVYCKQQLL (residues 37- 45 of HPV16 protein E6)

20 VYCKQQLLR (residues 38- 46 of HPV16 protein E6)

QQLLRREVY (residues 42- 50 of HPV16 protein E6)

IVYRDGNPY (residues 59- 67 of HPV16 protein E6)

YAVCDKCLK (residues 67- 75 of HPV16 protein E6)

AVCDKCLKF (residues 68- 76 of HPV16 protein E6)

25 VCDKCLKFY (residues 69- 77 of HPV16 protein E6)

KFYISKISEY (residues 75- 83 of HPV16 protein E6)

KISEYRHYC (residues 79- 87 of HPV16 protein E6)

ISEYRHYCY (residues 80- 88 of HPV16 protein E6)

RHYCYSLYG (residues 84- 92 of HPV16 protein E6)

30 SLYGTTLEQ (residues 89- 97 of HPV16 protein E6)

TTLEQQYNK (residues 93-101 of HPV16 protein E6)

QQYNKPLCD (residues 97-105 of HPV16 protein E6)

LIRCINCQK (residues 107-115 of HPV16 protein E6)

HLDDKKQRFH (residues 125-133 of HPV16 protein E6)

35 CMSCCRSSR (residues 143-151 of HPV16 protein E6)

SCCRSSRTR (residues 145-153 of HPV16 protein E6)

CCRSSRTRR (residues 146-154 of HPV16 protein E6)  
HYNIVTFCC (residues 51- 59 of HPV16 protein E7)  
YNIVTFCKK (residues 52- 60 of HPV16 protein E7)  
CCKCDSTLR (residues 58- 66 of HPV16 protein E7)  
KCDSTLRLC (residues 60- 68 of HPV16 protein E7), and  
a fragment, homolog, isoform, derivative, genetic

variant or conservative variant of any one of these amino acid  
sequences which has the ability to bind to human MHC Class I  
allele HLA-A3.2.

11. A peptide according to claim 1, wherein said amino acid  
sequence has the ability to bind to human MHC Class I allele HLA-  
A11.2.

12. A peptide according to claim 1, comprising an amino acid  
sequence derived from protein E6 or E7 of HPV16, wherein said  
amino acid sequence has the ability to bind to human MHC Class I  
allele HLA-A11.2 and is selected from the group consisting of:

AMFQDPQER (residues 7- 15 of HPV16 protein E6)  
IILECVYCK (residues 33- 41 of HPV16 protein E6)  
CVYCKQQLL (residues 37- 45 of HPV16 protein E6)  
VYCKQQLLR (residues 38- 46 of HPV16 protein E6)  
QQLLRREVY (residues 42- 50 of HPV16 protein E6)  
IVYRDGNPY (residues 59- 67 of HPV16 protein E6)  
YAVCDKCLK (residues 67- 75 of HPV16 protein E6)  
AVCDKCLKF (residues 68- 76 of HPV16 protein E6)  
VCDKCLKFY (residues 69- 77 of HPV16 protein E6)  
KISEYRHYC (residues 79- 87 of HPV16 protein E6)  
ISEYRHYCY (residues 80- 88 of HPV16 protein E6)  
LIRCINCQK (residues 107-115 of HPV16 protein E6)  
TGRCMSSCR (residues 140-148 of HPV16 protein E6)  
CMSSCRSSR (residues 143-151 of HPV16 protein E6)  
SSCRSSRTR (residues 145-153 of HPV16 protein E6)  
HYNIVTFCC (residues 51- 59 of HPV16 protein E7)  
YNIVTFCKK (residues 52- 60 of HPV16 protein E7)  
CCKCDSTLR (residues 58- 66 of HPV16 protein E7)  
VCPICSQKP (residues 90- 98 of HPV16 protein E7), and  
a fragment, homolog, isoform, derivative, genetic

T cell response effective against HPV, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

18. A pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-15 which is able to induce a HLA class I-restricted CD8<sup>+</sup> cytotoxic T cell response effective against HPV, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

19. A method of prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-15.

20. A method of prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of an immunogenic form of a peptide according to any one of the claims 1-15 which is able to induce a T cell response effective against HPV.

21. A method of prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases with a human individual, comprising administering to said human individual a prophylactically or therapeutically effective amount of an immunogenic form of a peptide according to any one of the claims 1-15 which is able to induce a HLA class I-restricted CD8<sup>+</sup> cytotoxic T cell response effective against HPV.

22. A peptide according to any one of claims 1-15 for prophylactically or therapeutically inducing in a human individual a HLA class I-restricted CD8<sup>+</sup> cytotoxic T cell response effective against HPV.

23. Use of a peptide according to any one of claims 1-15 for preparing a pharmaceutical composition for prophylactically or therapeutically inducing in a human individual a HLA class I-restricted CD8<sup>+</sup> cytotoxic T cell response effective against HPV.

variant or conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A11.2.

13. A peptide according to claim 1, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A24.

14. A peptide according to claim 1, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A24 and is selected from the group consisting of:

MHQKRTAMF (residues 1- 9 of HPV16 protein E6)

LQTTIHDI (residues 26- 34 of HPV16 protein E6)

VYCKQQLLR (residues 38- 46 of HPV16 protein E6)

LLRREVDYDF (residues 44- 52 of HPV16 protein E6)

VYDFAFRDL (residues 49- 57 of HPV16 protein E6)

PYAVCDKCL (residues 66- 74 of HPV16 protein E6)

KCLKFYSKI (residues 72- 80 of HPV16 protein E6)

EYRHYCYSL (residues 82- 90 of HPV16 protein E6)

HYCYSLYGT (residues 85- 93 of HPV16 protein E6)

CYSLYGTTL (residues 87- 95 of HPV16 protein E6)

RFHNIRGRW (residues 131-139 of HPV16 protein E6)

RAHYNIVTF (residues 49- 57 of HPV16 protein E7), and

a fragment, homolog, isoform, derivative, genetic

variant or conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A24.

15. A peptide according to any one of the claims 1-14, having a length of from 9 to 12 amino acids.

16. A pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-15, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

17. A pharmaceutical composition containing a prophylactically or therapeutically effective amount of a peptide according to any one of the claims 1-15 which is able to induce a

Binding of HPV 16 E6/7 peptides to HLA-A2.1




FIG. 1

This Page Blank (uspto)

Binding of HPV18 E6/7 peptides to HLA-A2.1




FIG. 2

This Page Blank (uspio)

3/3




FIG. 3

This Page Blank (uspto)

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/NL 93/00093

**I. CLASSIFICATION OF SUBJECT MATTER** (if several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC  
 Int.Cl. 5 C07K7/06; A61K37/02

**II. FIELDS SEARCHED**Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	C07K ; A61K

Documentation Searched other than Minimum Documentation  
 to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>

**III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>**

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	<p>EUROPEAN JOURNAL OF CANCER  vol. 28, no. 2/3, February 1992,  pages 326 - 333  ANNETTE ALTMANN ET AL. 'Definition of  immunogenic determinants of the human  papillomavirus type 16 nucleoprotein E7'  * Abstract *  see page 327, left column, paragraph 1  -paragraph 2; table 1  see page 329, right column, paragraph 2 -  page 330, right column, paragraph 1  see page 331, left column, last paragraph  - right column, paragraph 2  see page 331, right column, paragraph 7 -  page 332, left column, paragraph 1</p> <p style="text-align: center;">---</p> <p style="text-align: right;">-/--</p>	1,2

<sup>10</sup> Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

**IV. CERTIFICATION**

Date of the Actual Completion of the International Search

20 SEPTEMBER 1993

Date of Mailing of this International Search Report

29 -09- 1993

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

MONTERO LOPEZ B.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 88, no. 13, 1 July 1991, WASHINGTON US pages 5887 - 5891 ROBERT W. TINDLE ET AL. 'A ' see page 5887, left column, paragraph 1 -last paragraph; figure 1A see page 5888, left column, paragraph 5 - page 5889, left column, paragraph 1 see page 5890, right column, last paragraph - page 5891, left column, last paragraph</p> <p>---</p>	1,2,4,5, 15,16,17
A	<p>JOURNAL OF VIROLOGY vol. 65, no. 9, September 1991, pages 4681 - 4690 SARAH A. COMERFORD ET AL. 'Identification of T- and B-cell epitopes of the E-7 protein of human papillomavirus type 16' * abstract * see page 4685, left column, paragraph 2 - right column, paragraph 1; figure 1</p> <p>---</p>	1,2,5,8, 10,12, 14,15
A	<p>WO,A,9 205 248 (BRISTOL-MYERS SQUIBB COMPANY) 2 April 1992 see page 7, line 9 - page 9, line 18 see page 26, line 22 - page 27, line 15; claims 1,7-10,13,24,38-48</p> <p>---</p>	1,16,17, 19,20
A	<p>EP,A,0 375 555 (MEDGENIX GROUP, S.A.) 27 June 1990  see page 4, line 4 - line 19</p> <p>---</p>	1,2,4,5, 6,10,12, 14
A	<p>EP,A,0 456 197 (BEHRINGWERKE) 13 November 1991 see page 2, line 29 - line 54</p> <p>---</p>	1,3,6,16
P,X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 89, no. 17, 1 September 1992, WASHINGTON US pages 7871 - 7875 HANS J. STAUSS ET AL. 'Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus'</p> <p>-----</p>	1,2

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

NL 9300093  
SA 74419

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 20/09/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9205248	02-04-92	AU-A- 8762991	15-04-92
		CN-A- 1067382	30-12-92
EP-A-0375555	27-06-90	FR-A- 2641081	29-06-90
		CA-A- 2006118	23-06-90
		JP-A- 2291297	03-12-90
EP-A-0456197	13-11-91	DE-A- 4015044	14-11-91
		AU-A- 7621291	14-11-91
		JP-A- 4227000	17-08-92

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/NL.93/00093

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos. 20-21  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark : Although claims 20-21 are directed to a method of treatment of (diagnostic method practised on) the human body the search has been carried out and based on the alleged effects of the compound.**
2. ☐ Claims Nos. 22-23  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos. 24-25  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos. 20-21.
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. 20-21.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum)

PCT 0268

### Box No. I TITLE OF INVENTION

Peptides of human papilloma virus for use in human T cell response inducing compositions.

### Box No. II APPLICANT

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)

Rijksuniversiteit Leiden  
Stationsweg 46  
2312 AV Leiden  
the Netherlands

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (i.e. country) of nationality:

NL

State (i.e. country) of residence:

NL

This person is applicant for the purposes of:

☐ all designated States

☒ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

### Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)

Kast, Wybe Martin  
Maria Rutgersweg 106  
2331 NX Leiden  
the Netherlands

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

NL

State (i.e. country) of residence:

NL

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)

Melief, Cornelis Joseph Maria  
Johan Vermeerstraat 15  
2102 BT Heemstede  
the Netherlands

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

NL

State (i.e. country) of residence:

NL

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

This Page Blank (uspto)

## Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

*If none of the following sub-boxes is used, this sheet is not to be included in the request.*Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

Sette, Alessandro D.  
 5551 Linda Rosa Avenue  
 La Jolla, CA 92037  
 United States of America

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality:  
ITState (i.e. country) of residence:  
U.S.A.This person is applicant  
for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

Sidney, John C.  
 8541 D Villa La Jolla Drive  
 La Jolla, CA 92037  
 United States of America

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality:  
U.S.A.State (i.e. country) of residence:  
U.S.A.This person is applicant  
for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

This person is:

- ☐ applicant only
- ☐ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant  
for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

This person is:

- ☐ applicant only
- ☐ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant  
for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

*This Page Blank (uspto)*

**Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:



agent



common representative

Name and address: *(Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.)*

Smulders, Th.A.H.J., c.s.  
c/o VEREENIGDE OCTROOIBUREAUX  
Nieuwe Parklaan 97  
2587 BN The Hague.  
the Netherlands

Telephone No.

070 - 3500464

Facsimile No.

070 - 3522723

Teleprinter No.



Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

**Box No.V DESIGNATION OF STATES**

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

**Regional Patent**

**EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT



**OA OAPI Patent:** Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Gabon, Guinea, Mali, Mauritania, Senegal, Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

**National Patent (if other kind of protection or treatment desired, specify on dotted line):**

AT Austria



MG Madagascar



AU Australia



MN Mongolia



BB Barbados



MW Malawi



BG Bulgaria



NL Netherlands



BR Brazil



NO Norway



CA Canada



NZ New Zealand



CH and LI Switzerland and Liechtenstein



PL Poland



CZ Czech Republic



PT Portugal



DE Germany



RO Romania



DK Denmark



RU Russian Federation



ES Spain



SD Sudan



FI Finland



SE Sweden



GB United Kingdom



SK Slovak Republic



HU Hungary



UA Ukraine



JP Japan



US United States of America



KP Democratic People's Republic of Korea



KR Republic of Korea



VN Vietnam



LK Sri Lanka



NE Niger



LU Luxembourg




Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of \_\_\_\_\_

The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

This Page Blank (uspto)

<b>Box No. VI PRIORITY CLAIM</b>		Further priority claims are indicated in the Supplemental Box <input checked="" type="checkbox"/>	
The priority of the following earlier application(s) is hereby claimed:			
Country (in which, or for which, the application was filed)	Filing Date (day/month/year)	Application No.	Office of filing (only for regional or international application)
item (1) EP	05.05.92 5 May 1992	92201252.1	
item (2) EP	10.12.92 10 December 1992	92203870.8	
item (3) EP	01.02.93 1 February 1993	93200243.9	
Mark the following check-box if the certified copy of the earlier application is to be issued by the Office which for the purposes of the present international application is the receiving Office (a fee may be required): <input type="checkbox"/> The receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s) : _____			
<b>Box No. VII EARLIER SEARCH</b>			
Fill in where a search (international, international-type or other) by the International Searching Authority has already been carried out or requested and the Authority is now requested to base the international search, to the extent possible, on the results of that earlier search. Identify such search or request either by reference to the relevant application (or the translation thereof) or by reference to the search request: Country (or regional Office): EP      Date (day/month/year): 5 May 1992      Number: 92201252.1			
<b>Box No. VIII CHECK LIST</b>			
This international application contains the following number of sheets: 1. request : 5 sheets 2. description : 50 sheets 3. claims : 6 sheets 4. abstract : 1 sheets 5. drawings : 3 sheets Total : 65 sheets		This international application is accompanied by the item(s) marked below: 1. <input type="checkbox"/> separate signed power of attorney      5. <input checked="" type="checkbox"/> fee calculation sheet 2. <input type="checkbox"/> copy of general power of attorney      6. <input type="checkbox"/> separate indications concerning deposited microorganisms 3. <input type="checkbox"/> statement explaining lack of signature      7. <input type="checkbox"/> nucleotide and/or amino acid sequence listing (diskette) 4. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):      8. <input type="checkbox"/> other (specify):	
Figure No. _____ of the drawings (if any) should accompany the abstract when it is published.			
<b>Box No. IX SIGNATURE OF APPLICANT OR AGENT</b>			
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request). <div style="text-align: center; margin-top: 20px;">             Drs. M. J. Hatzmann         </div>			

For receiving Office use only	
1. Date of actual receipt of the purported international application:	2. Drawings:  <input type="checkbox"/> received:  <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority specified by the applicant: ISA/	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid

Date of receipt of the record copy by the International Bureau:	For International Bureau use only
---	-----------------------------------

This Page Blank (uspio)

**Supplemental Box**      *If the Supplemental Box is not used, this sheet need not be included in the request.*

*Use this box in the following cases:*

1. *If, in any of the Boxes, the space is insufficient to furnish all the information:*

*in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient;*

*in particular:*

  - (i) *if more than three persons are involved as applicants and/or inventors and no "continuation sheet" is available:*

*in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III;*
  - (ii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked:*

*in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State or States (and/or, where applicable, European or OAPI patent) for the purposes of which the named person is applicant;*
  - (iii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America:*

*in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State or States (and/or, where applicable, European or OAPI patent) for the purposes of which the named person is inventor;*
  - (iv) *if, in addition to the agent(s) indicated in Box No. IV, there are further agents:*

*in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;*
  - (v) *if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," "certificate of addition," or "inventor's certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "Continuation" or "Continuation-in-part":*

*in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;*
  - (vi) *if there are more than three earlier applications whose priority is claimed:*

*in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.*
2. *If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty:*

*in such case, write "Statement Concerning Non-Prejudicial Disclosures or Exceptions to Lack of Novelty" and furnish that statement below.*

**Continuation of Box No. VI      Priority claim**

	<u>Country</u>	<u>Filing Date</u>	<u>Application No.</u>
item (4)	EP	05.03.93 5 March 1993	93200621.6

This Page Blank (uspio)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

This Page Blank (uspto)